Business Report: Company Analysis In A Developing Nation

Business Report: Company Analysis in a Developing Nation Context

Analyze a selected company from the provided list in the context of a developing nation aiming to foster industrial growth while safeguarding national interests. Your report should include an executive summary, detailed company description, analysis of international strategy, marketing approach, supply chain, HR management, and an assessment of risks and benefits. Conclude with a clear recommendation regarding allowing the company to operate in your country. Use at least six credible sources, cite all data in APA style, and ensure the report is concise, well-structured, and free of plagiarism.

Paper For Above instruction

In this analysis, I have selected GlaxoSmithKline (GSK) as the multinational company to evaluate in the context of a developing nation seeking economic growth through foreign direct investment (FDI). GSK, a leading global healthcare company headquartered in the United Kingdom, specializes in pharmaceuticals, vaccines, and consumer healthcare products. Its substantial revenue, diverse product portfolio, and recent expansion efforts make it a noteworthy subject for this analysis.

Company Description

GlaxoSmithKline operates across multiple industries within the healthcare sector, including pharmaceuticals, vaccines, and consumer health products. The company reported revenues exceeding $44 billion in 2022, emphasizing its significant market presence. With approximately 100,000 employees worldwide, GSK maintains a robust global footprint, including manufacturing plants, research centers, and sales offices across North America, Europe, Asia, and emerging markets.

Over recent years, GSK has experienced steady growth, driven by expanding vaccine markets and a strategic focus on emerging economies. Notable recent developments include the development and distribution of COVID-19 vaccines and acquisitions aimed at broadening its product range (GSK Annual Report, 2022). The company’s stability and ongoing innovation suggest a resilient and adaptable enterprise, although challenges such as regulatory hurdles and patent expirations remain pertinent.

Company’s International Strategy

GSK’s international strategy emphasizes a combination of standardization and localization, tailored to its target markets' needs. It primarily relies on a transnational strategy that balances local responsiveness with global efficiency. This approach allows GSK to adapt its products to regional health issues and regulatory requirements while leveraging economies of scale in manufacturing and R&D (Dunning, 1998). Its focus on emerging markets such as India, China, and parts of Africa exemplifies its commitment to tapping into fast-growing economies with unmet healthcare needs.

Competitors like Pfizer and Sanofi adopt similar strategies, although some may emphasize either localization or global standardization more heavily depending on their product lines. For example, Pfizer tends to standardize its products more globally, while Sanofi emphasizes local adaptation depending on regional health concerns. GSK’s strategy is thus distinct in its nuanced approach, aiming to establish a presence in diverse markets by understanding local health challenges and building partnerships with local governments and organizations (Bartlett & Ghoshal, 1989).

Company’s Marketing Approach

GSK targets various regions, prioritizing emerging markets where healthcare needs are rising and competitors’ presence is substantial. Its marketing approach is region-specific, employing both standardized and customized elements. In developed markets, GSK relies on advanced promotion, digital marketing, and scientifically driven messaging to healthcare providers and consumers. Conversely, in emerging markets, strategies focus on affordability, accessibility, and partnerships with governments and NGOs to increase vaccine and medication penetration (Keller, 2012).

Regarding the marketing mix, GSK emphasizes product standardization in core pharmaceuticals while customizing formulations to meet local regulations and preferences. Distribution channels include partnerships with local distributors, government health programs, and retail outlets. Promotion methods extend from direct-to-consumer advertising in mature markets to community outreach and education campaigns in developing regions. Pricing strategies are adapted to local purchasing power, often involving tiered pricing models (Kotler & Keller, 2016). These tailored marketing strategies have enabled GSK to establish a strong foothold in diverse markets, fostering trust and accessibility.

Company’s Supply Chain Approach

GSK produces many of its major pharmaceuticals and vaccines in regional manufacturing facilities. Its supply chain choices are driven by factors including proximity to key markets, technological capabilities, cost efficiencies, and regulatory compliance. For instance, the company manufacturers vaccines in India and China to serve the local markets efficiently, benefitting from lower production costs and regional expertise (Christopher, 2016). This regional production also mitigates risks associated with supply disruptions and currency fluctuations.

Alternatively, GSK sources raw materials and active pharmaceutical ingredients (APIs) globally, often from countries with established chemical and biotech industries. Such decisions are influenced by component quality, cost, and supplier reliability. The company’s emphasis on a flexible and resilient supply chain enables it to respond swiftly to changing demands and regulatory requirements, which is critical in the healthcare sector (Chopra & Meindl, 2016).

Company’s Human Resource Management (HRM) Approach

GSK’s HRM strategy emphasizes diversity, inclusion, and local talent development across its international subsidiaries. In developing countries, GSK often recruits and trains local healthcare professionals, aligning staffing policies with local labor laws and cultural contexts. The company invests in expatriate management, providing cross-cultural training and expatriate packages to ensure managerial consistency and transfer of corporate values (Dowling et al., 2013). Furthermore, GSK’s policies prioritize employee benefits and ethical standards, fostering a committed workforce that contributes positively to its operations in diverse environments.

Analysis of Risks and Benefits

Allowing GSK to operate in the developing country presents considerable benefits, including access to advanced healthcare products, technology transfer, job creation, and health infrastructure development. Its presence can stimulate local industries, increase health awareness, and promote economic growth. Additionally, GSK’s expertise in clinical research and manufacturing could align with national priorities of health improvement and capacity building (Lall & Streeten, 1980).

However, risks involve potential exploitation of natural resources, intellectual property concerns, and the possibility of market dominance that may discourage local competitors. There are also worries about compliance with local regulations, cultural insensitivity, and the possibility that profit motives could overshadow social objectives (Rodrik, 2017). Moreover, if GSK fails to adapt to local health needs or engages in practices misaligned with national development goals, public trust could be compromised.

Recommendation and Conclusion

Based on the comprehensive analysis, it is recommended that the government permits GSK to establish operations in the country, provided that strict regulatory measures are enforced. These include requirements for local employment quotas, technology transfer agreements, and compliance with health standards. GSK’s global expertise and local adaptation strategies align with the country’s development objectives, offering substantial benefits in healthcare access and economic stimulation.

Nevertheless, safeguards should be in place to ensure that community interests are protected, and a monitoring framework established to evaluate ongoing adherence to national policies. Facilitating partnerships between GSK and local health authorities could enhance mutually beneficial outcomes and ensure that the company’s presence supports sustainable development.

References

  • Chopra, S., & Meindl, P. (2016). Supply Chain Management: Strategy, Planning, and Operation. Pearson.
  • Dunning, J. H. (1998). Regions, globalization, and the knowledge-based economy. Oxford University Press.
  • Dowling, P. J., Festing, M., & Engle, A. D. (2013). International Human Resource Management. Cengage Learning.
  • GSK. (2022). Annual Report 2022. GlaxoSmithKline.
  • Keller, K. L. (2012). Branding and Brand Equity. In Handbook of Marketing Strategy (pp. 245-270). Sage Publications.
  • Kotler, P., & Keller, K. L. (2016). Marketing Management (15th ed.). Pearson.
  • Lall, S., & Streeten, P. (1980). Foreign Investment and Development: A Critique. World Development, 8(4), 319-328.
  • Rodrik, D. (2017). Straight Talk on Trade: Ideas for a Sane World Economy. Princeton University Press.
  • GSK. (2022). Company Annual Report. Retrieved from https://www.gsk.com/en-gb/investors/annual-report/
  • Christopher, M. (2016). Logistics & Supply Chain Management. Pearson.

Related Assignments